APAC Pharmaceutical Contract Manufacturing Organization Market (2022 – 2027): Injectable Dose Formulations Holds Significant Market Share – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Asia-Pacific Pharmaceutical Contract Manufacturing Organization Market – Growth, Trends, Forecasts (2022 – 2027)” report has been added to ResearchAndMarkets.com’s offering.

The Asia Pacific pharmaceutical contract manufacturing organization market is expected to register a CAGR of 9.4% during the forecast period 2020 – 2025.

China is a country with low labor wages, which alone can lower the manufacturing costs of the pharmaceutical companies by as much as 30%. Along with it, low capital and overhead costs (compared to that of the United States and Europe), tax incentives, and undervalued currency combine to provide a significant cost advantage for pharmaceutical companies outsourcing to China.

Key Highlights

Another factor driving the pharmaceutical CMO market in China is the country’s Western-trained skilled workers. Majority of the workers who are trained in Western countries return to China to find work because of strict immigration policies an d significant unemployment among the European and American pharmaceutical workers.

India is also taking advantage of the growth in the domestic CMO market, encouraging the Japanese pharmaceutical industries to setup their locations in the country, either wholly owned or in partnership with Indian companies. Additionally, India has until now allowed 100% FDI through the automatic route. This 100% FDI under the automatic route has been allowed in contract manufacturing to give a big boost to domestic manufacturing.

The CMO market in Japan is still immature. However, the country witnessed incremental growth over the past few years. The Japanese CMO market witnessed a growth of about 30%, following the recognition to separate manufacturing and sales by the Pharmaceutical Affairs Act. The growth trend has been continuing ever since. The number of CMO manufacturers of significant size in Japan is low and includes players, like Bushu Pharmaceuticals, Nipro Pharma, and CMIC.

With extensive governmental reforms in drug pricing, structural changes, and unpredictability in reimbursement and pricing decisions, many pharmaceutical companies in Australia are being challenged. However, the country is geographically well-placed in relation to pharmaceutical exports, owing to its proximity to the emerging markets of South Asia.

The recent medical outbreak of COVID-19 has its epicenter in Wuhan, a Chinese city that was once known for its heavy industry and steel and was poised to become a burgeoning center for bio- pharmaceutical manufacturing. Such outbreaks may lead to the disruption of drug supply and manufacturers are required to notify the US Food and Drug Administration when that happens. As the outbreak becomes more widespread, it becomes a burden for pharmaceutical plants around the world to maintain the inventory required for manufacturing, as China is a major supplier of raw materials.

Key Market Trends

Injectable Dose Formulations Holds Significant Market Share

The pharmaceutical contract manufacturing market is estimated to experience an upward trend, with the rise in demand for injectable drugs, especially in cancer research. Owing to the robust demand for oncology and other high-potency drugs (such as antibody conjugates, steroids, and IV fluids that require quick onset of action), cytotoxics are expected to be the key growth drivers for the injectable dose formulation segment.

Injectable drugs provide higher returns, as compared to other drug formulation types. Therefore, higher ROI, therapeutic efficiency, and rapid onset of action are expected to drive the growth of the injectable formulation segment.

Robust growth rates may be expected from the number of promising late-stage clinical compounds in the pipeline for cancer therapy. Anti-cancer drugs represent a significant share of nearly 50% of the pipeline products.

The majority of the biologic drug product formulations as well as fill and finish services are being outsourced to CMOs, while the big pharmaceutical companies focus on the discovery and development of drug substrates and products. Although other dosage formulation manufacturing involves lesser capital investment and operating costs, the profit margins are higher for sterile injectable dose formulations.

India Occupies Significant Market Share

With the advent of multinational pharmaceutical organizations and their rapidly growing presence in India, the concept of contract manufacturing has steadily evolved and quickly adapted to encompass services, such as formulation development, basic manufacturing of medicinal products, stability studies, and various stages of clinical trials.

India has a far superior advantage, over many nations, in the basic manufacturing of medical drugs and products due to resources, such as large manpower, knowledgeable workforce, and WHO-GMP approved production principles.

Scale-up of drug synthesis and late clinical trials have become a profitable protocol in this region. Along with it, DTAB (Drug Technical Advisory Board) has agreed to grant wavier to late stage (Phase III) studies of certain drugs in India, which are from the regulated markets of Europe and the United States. This incentive step translates into enormous cost savings for pharmaceutical companies, thereby increasing their focus on India.

The COVID -19 outbreak is expected to hit India’s pharmaceutical sector as well; in fact, it has already started. Indian drug manufacturers are dependent on China for sourcing their drug ingredients or active pharmaceutical ingredients (API) to a large extent. The prices of key ingredients for the manufacturing of drugs are rising on account of the virus outbreak. According to data available with the Pharmaceutical Export Promotion Council (Pharmexcil), the cost of key ingredients has gone up by 50- 60% already.

Latest data compiled by India’s drug regulatory authority revealed that 57 APIs required for crucial antibiotics, vitamins, and hormones or steroids may go out of stock, in case of a prolonged lockdown in China. This may, in turn, have a significant effect on the pharmaceutical manufacturing industry.

For more information about this report visit https://www.researchandmarkets.com/r/59oxwa

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900